Safety profile of different low-molecular weight heparins used at therapeutic dose.
about
Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancyMonitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal InsufficiencyNew and generic anticoagulants and biosimilars: safety considerations.Treatment dosing of low-molecular-weight heparins and the dose cap dilemma: considerations for patients in Canada.Pharmacological thromboprophylaxis and total hip or knee replacement.A Review of the Evidence to Support Neuromuscular Electrical Stimulation in the Prevention and Management of Venous Disease.A need for evidence-based clinical practice guidelines for the use of heparins in the elderly.Rapid point-of-care assay of enoxaparin anticoagulant efficacy in whole blood.In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study.Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight.Influence of Body Mass Index on the Activated Clotting Time Under Weight-Based Heparin Dose.Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment.Association Between Low-Molecular-Weight Heparin and Risk of Bleeding Among Hemodialysis Patients: A Retrospective Cohort Study
P2860
Q24234729-1416E966-08AA-40C5-A3EE-1DBAAEC20174Q35549780-14C80040-4237-4398-B445-7C2D49E73463Q35851245-6631AE77-98A7-465F-991F-36BF289A6B6FQ36484329-6560A0F4-54E4-4762-B852-38813339A5B6Q37821142-6F695E4B-CE00-47C0-9D41-35D3276BA232Q38000240-A11B982B-8DB1-4B13-AE0E-793A8584228FQ38696813-E38A89E6-F7C9-4D32-8168-6CF893DD2505Q38952572-E5C2F485-4621-44B1-B886-CEDA571D1064Q40270973-860C68FB-2ADE-4170-9833-22DE130F7F04Q41460353-E256F99C-EAF4-4DD4-A4CD-1907E6881F4EQ42163608-13D8334B-8F61-4402-81B9-12503C0835B9Q46831995-9AE63B17-0ED4-494A-8082-E24A2722AE51Q47353736-7763CFB5-5772-44E3-BE52-D5948A1E5D5DQ47424028-6BE84102-5E65-4928-B7DE-AA7027B76375Q50002162-D44B5DB2-0384-4156-BA90-8C07095EBC49Q55455218-A0461CF0-82CA-40DF-989D-BEEA9E0C5410Q58803291-9AD37203-A2BD-4AA1-884C-C90D57FE11E7
P2860
Safety profile of different low-molecular weight heparins used at therapeutic dose.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Safety profile of different low-molecular weight heparins used at therapeutic dose.
@ast
Safety profile of different low-molecular weight heparins used at therapeutic dose.
@en
type
label
Safety profile of different low-molecular weight heparins used at therapeutic dose.
@ast
Safety profile of different low-molecular weight heparins used at therapeutic dose.
@en
prefLabel
Safety profile of different low-molecular weight heparins used at therapeutic dose.
@ast
Safety profile of different low-molecular weight heparins used at therapeutic dose.
@en
P2093
P1433
P1476
Safety profile of different low-molecular weight heparins used at therapeutic dose.
@en
P2093
Eric Pautas
Isabelle Gouin-Thibault
Virginie Siguret
P304
P356
10.2165/00002018-200528040-00005
P577
2005-01-01T00:00:00Z
P6179
1007256967